Related Experiment Video
Updated: Jun 22, 2026
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy
Junli Wu1, Jishu Wei, Kai Meng
1Department of General Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
Abstract:
Recent research has indicated that MUC4 plays an important role in the development of many tumors and may prove useful as a novel cancer immunotherapy target. We aimed to identify HLA-A*0201-restrictive cytotoxic T lymphocyte (CTL) epitopes of the cancer-associated antigen MUC4. The MUC4 sequence was scanned for immunogenic peptides using HLA-binding prediction software. Dendritic cells (DCs) from peripheral blood mononuclear cells (PBMCs) were induced by cytokines. Five possible CTL epitopes were selected by software analysis, synthesized, and used to pulse mature DCs. The CD8(+) T cells from PBMCs from an HLA-A*0201 healthy donor were stimulated with autologous MUC4-peptide-loaded DCs and expanded in vitro. T cell activation was assessed by ELISPOT, and cytotoxicity was determined by (51)chromium ((51)Cr)-release assays. Our results show that CTLs induced by peptide P01204 could lyse T2 cells pulsed with peptide P01204 and HCT-116 cells (MUC4(+), HLA-A2(+)). Compared with a control peptide, P01204 increased the number of IFN-gamma producing T cells. Overall, these results suggest that P01204 is a novel HLA-A*0201-restrictive CTL epitope of the cancer-associated antigen MUC4. This will provide a foundation for the development of tumor-specific peptide vaccines.
Insights
Researchers identified a novel MUC4 peptide, P01204, as a promising target for cancer immunotherapy. This HLA-A*0201-restrictive cytotoxic T lymphocyte (CTL) epitope shows potential for developing effective tumor-specific peptide vaccines.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Mucin 4 (MUC4) is implicated in tumor development and represents a potential target for cancer immunotherapy.
- Identifying specific epitopes is crucial for developing targeted immunotherapies.
Purpose of the Study:
- To identify HLA-A*0201-restrictive cytotoxic T lymphocyte (CTL) epitopes derived from the MUC4 antigen.
- To evaluate the potential of these epitopes as targets for cancer immunotherapy.
Main Methods:
- Bioinformatic prediction of MUC4-derived peptides binding to HLA-A*0201.
- Synthesis of predicted peptides and pulsing of mature dendritic cells (DCs).
- In vitro stimulation and expansion of CD8(+) T cells using MUC4-peptide-loaded DCs, followed by ELISPOT and (51)Cr-release assays to assess T cell activation and cytotoxicity.
Main Results:
- Five potential CTL epitopes were identified computationally.
- Peptide P01204 successfully induced CTLs capable of lysing MUC4-positive, HLA-A2-positive cancer cells (HCT-116) and T2 cells pulsed with the peptide.
- P01204 significantly increased the number of interferon-gamma (IFN-γ)-producing T cells compared to a control peptide.
Conclusions:
- P01204 is a novel, HLA-A*0201-restrictive CTL epitope of the cancer-associated antigen MUC4.
- This finding lays the groundwork for developing MUC4-targeted tumor-specific peptide vaccines for cancer immunotherapy.
